Arthur Davis, NP
Family · Tifton, GANPI 1366962227
Payments from drug & device makers
Across 191 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$478
- AbbVie$439
- Novo Nordisk$414
- Dexcom, Inc.$295
- Lilly USA, LLC$241
- Amgen$167
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,361100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $478 |
| AbbVie | 27 | $439 |
| Novo Nordisk | 21 | $414 |
| Dexcom, Inc. | 17 | $295 |
| Lilly USA, LLC | 15 | $241 |
| Amgen(2 entities) | 9 | $167 |
| Pfizer | 7 | $147 |
| Bayer | 6 | $134 |
| Shield Therapeutics Inc | 6 | $129 |
| GSK | 8 | $128 |
| Amarin Pharma, Inc. | 7 | $126 |
| Johnson & Johnson | 6 | $84 |
| Abbott | 4 | $71 |
| Boehringer Ingelheim | 3 | $59 |
| Eisai Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Insulet Corporation | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Corium, LLC | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Antares Pharma, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$3,361 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 60 | $66,345 |
| OzempicSemaglutide | 37 | $50,143 |
| TrulicityDulaglutide | 28 | $34,999 |
| JardianceEmpagliflozin | 14 | $24,975 |
| FarxigaDapagliflozin Propanediol | 13 | $21,447 |
| EliquisApixaban | 17 | $14,773 |
| Repatha SureclickEvolocumab | 12 | $7,628 |
| Liothyronine Sodium | 33 | $2,008 |
| Montelukast Sodium | 96 | $1,081 |
| SynthroidLevothyroxine Sodium | 13 | $1,071 |
| Levothyroxine Sodium | 74 | $871 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 11 | $765 |
| Dexamethasone | 62 | $661 |
| Testosterone Cypionate | 13 | $655 |
| Omeprazole | 54 | $632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $241 | $101,34588 claims |
| Novo NordiskOzempic | $414 | $50,14337 claims |
| Boehringer IngelheimJardiance | $59 | $24,97514 claims |
| AstraZenecaFarxiga | $478 | $21,44713 claims |
| PfizerEliquis | $147 | $14,77317 claims |
| AbbVieSynthroid | $439 | $1,07113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Tifton
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.